Metropolis Healthcare Ratios

Metropolis Healthcare Ltd Ratios

The Metropolis Healthcare Ltd Ratios page provides a complete fundamental analysis of Metropolis Healthcare Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Metropolis Healthcare Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Metropolis Healthcare Ltd (NSE: METROPOLIS, BSE: 542650) is currently trading at ₹1947.80, with a market capitalization of ₹100.91B. As a major player in the Health services sector and Medical/Nursing services industry, Metropolis Healthcare Ltd remains a key stock for fundamental analysis using Metropolis Healthcare Ltd Ratios.

Metropolis Healthcare Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Metropolis Healthcare Ltd P/E ratio currently stands at 55.50, making it one of the most tracked metrics in Metropolis Healthcare Ltd Ratios.

Historically, the Metropolis Healthcare Ltd P/E ratio has shown strong fluctuations:

• 2024: 55.50
• 2023: 69.42
• 2022: 44.90
• 2021: 48.89
• 2020: 62.62

The decline in Metropolis Healthcare Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Metropolis Healthcare Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 6.08.

Historical P/B trend:

• 2024: 6.08
• 2023: 8.07
• 2022: 6.47
• 2021: 11.76

Metropolis Healthcare Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Metropolis Healthcare Ltd P/S ratio currently stands at 6.04, an important part of Metropolis Healthcare Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 6.04
• 2023: 7.35
• 2022: 5.59
• 2021: 8.52

A stable or declining Metropolis Healthcare Ltd P/S ratio indicates cautious market sentiment.

Metropolis Healthcare Ltd Price to Cash Flow Ratio (P/CF)

The Metropolis Healthcare Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 30.45.

Historical Metropolis Healthcare Ltd Price to Cash Flow Ratio:

• 2024: 30.45
• 2023: 33.82
• 2022: 26.42
• 2021: 40.84
• 2020: 44.19

The declining Metropolis Healthcare Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Metropolis Healthcare Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Metropolis Healthcare Ltd EV currently stands at ₹81.36B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 81.36B
• 2023: 89.49B
• 2022: 65.78B
• 2021: 106.71B

Metropolis Healthcare Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Metropolis Healthcare Ltd EV/EBITDA ratio is currently 25.92, a key metric in Metropolis Healthcare Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 25.92
• 2023: 29.83
• 2022: 21.70
• 2021: 29.73

Stable Metropolis Healthcare Ltd EV/EBITDA indicates balanced valuation.

Metropolis Healthcare Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Metropolis Healthcare Ltd D/E ratio is currently 0.15, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.15
• 2023: 0.18
• 2022: 0.27
• 2021: 0.43

Metropolis Healthcare Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Metropolis Healthcare Ltd ROE currently stands at 11.95%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.95
• 2023: 12.26
• 2022: 15.25
• 2021: 26.89

Metropolis Healthcare Ltd maintains stable profitability levels.

Metropolis Healthcare Ltd Ratios Analysis Summary

The Metropolis Healthcare Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Metropolis Healthcare Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Metropolis Healthcare Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.